A 12-month, single-blind, randomized, parallel group, multicenter study to investigate the efficacy and safety of ERL080A compared with MMF in de novo heart recipients.
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Mycophenolate sodium (Primary) ; Mycophenolate mofetil
- Indications Heart transplant rejection
- Focus Adverse reactions
- Sponsors Novartis
- 01 Nov 2011 Actual end date of the extension trial (NCT00238446) is Jun 2006.
- 01 Nov 2011 Actual end date of the extension trial (NCT00238446) is Jun 2006.
- 01 Nov 2011 Actual initiation date of the extension trial (NCT00238446) is Apr 2003.